Stock Repurchase Plan Initiated by OptimizeRx (NASDAQ:OPRX) Board of Directors

OptimizeRx (NASDAQ:OPRX) declared that its Board of Directors has approved a stock repurchase program on Thursday, March 5th, RTT News reports. The company plans to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.

OptimizeRx Trading Down 4.3%

OptimizeRx stock traded down $0.34 during mid-day trading on Thursday, hitting $7.53. The stock had a trading volume of 949,743 shares, compared to its average volume of 404,031. The stock has a 50-day simple moving average of $10.63 and a two-hundred day simple moving average of $14.80. The company has a current ratio of 3.05, a quick ratio of 3.05 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $140.36 million, a PE ratio of 19.67 and a beta of 1.20. OptimizeRx has a 12 month low of $3.99 and a 12 month high of $22.25.

OptimizeRx (NASDAQ:OPRX) last announced its quarterly earnings data on Saturday, January 31st. The company reported $0.51 earnings per share (EPS) for the quarter. OptimizeRx had a net margin of 0.03% and a return on equity of 6.37%. As a group, sell-side analysts forecast that OptimizeRx will post -0.33 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of OptimizeRx in a research report on Monday, December 22nd. Citizens Jmp lifted their price target on OptimizeRx from $23.00 to $24.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Wall Street Zen upgraded shares of OptimizeRx from a “buy” rating to a “strong-buy” rating in a research report on Sunday, December 14th. Zacks Research lowered shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, December 15th. Finally, Stephens dropped their target price on shares of OptimizeRx from $20.00 to $17.00 and set an “equal weight” rating for the company in a research note on Monday, November 17th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, OptimizeRx currently has an average rating of “Moderate Buy” and an average target price of $20.50.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.